Breast cancer is the most common cancer among Indian women and India accounts for almost one-third of the global breast cancer burden. The rapidly rising breast cancer mortality rates call for urgent and efficient management of breast cancer in India. In such a scenario, the U.S. Food and Drug Administration (FDA) recently approved Neratinib for the extended adjuvant treatment of early-stage, HER2-positive breast cancer.
US FDA approved Neratinib, a tyrosine kinase inhibitor, as extended adjuvant therapy for early-stage, HER2-positive breast cancer. For patients with HER2-positive breast cancer, Neratinib is the first extended adjuvant therapy i.e. a form of therapy that is taken after an initial treatment to further lower the risk of cancer coming back. Neratinib is indicated for adult patients who have been previously treated with a regimen that includes the monoclonal antibodies…
